Ceramide synthase 1 is regulated by proteasomal mediated turnover.

[1]  G. Meer,et al.  Membrane lipids: where they are and how they behave , 2008, Nature Reviews Molecular Cell Biology.

[2]  Yusuf A. Hannun,et al.  Principles of bioactive lipid signalling: lessons from sphingolipids , 2008, Nature Reviews Molecular Cell Biology.

[3]  Y. Hannun,et al.  A novel role for protein kinase Cδ‐mediated phosphorylation of acid sphingomyelinase in UV light‐induced mitochondrial injury , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  Y. Hannun,et al.  Involvement of sphingoid bases in mediating reactive oxygen intermediate production and programmed cell death in Arabidopsis , 2007, Cell Research.

[5]  A. Haimovitz-Friedman,et al.  Kinetic characterization of mammalian ceramide synthases: Determination of K m values towards sphinganine , 2007, FEBS letters.

[6]  P. V. Van Veldhoven,et al.  (Dihydro)ceramide Synthase 1–Regulated Sensitivity to Cisplatin Is Associated with the Activation of p38 Mitogen-Activated Protein Kinase and Is Abrogated by Sphingosine Kinase 1 , 2007, Molecular Cancer Research.

[7]  A. Huwiler,et al.  Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. , 2007, Critical reviews in oncology/hematology.

[8]  L. Obeid,et al.  Alterations of Ceramide/Sphingosine 1-Phosphate Rheostat Involved in the Regulation of Resistance to Imatinib-induced Apoptosis in K562 Human Chronic Myeloid Leukemia Cells* , 2007, Journal of Biological Chemistry.

[9]  F. Goñi,et al.  Sphingolipids and cell death , 2007, Apoptosis.

[10]  Y. Hannun,et al.  Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas , 2007, Molecular Cancer Therapeutics.

[11]  Y. Hannun,et al.  Protein Kinase C-induced Activation of a Ceramide/Protein Phosphatase 1 Pathway Leading to Dephosphorylation of p38 MAPK* , 2006, Journal of Biological Chemistry.

[12]  Y. Hannun,et al.  Necessary Role for the Lag1p Motif in (Dihydro)ceramide Synthase Activity* , 2006, Journal of Biological Chemistry.

[13]  A. Kihara,et al.  LASS3 (longevity assurance homologue 3) is a mainly testis-specific (dihydro)ceramide synthase with relatively broad substrate specificity. , 2006, The Biochemical journal.

[14]  Howard Riezman,et al.  Transmembrane topology of ceramide synthase in yeast. , 2006, The Biochemical journal.

[15]  S. Ben-Dor,et al.  When Do Lasses (Longevity Assurance Genes) Become CerS (Ceramide Synthases)? , 2006, Journal of Biological Chemistry.

[16]  P. Krzyzanowski,et al.  Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase Cι-mediated attenuation of p38 MAP kinase signaling , 2006, Oncogene.

[17]  D. Goldenberg,et al.  Sphingolipid targets in cancer therapy , 2006, Molecular Cancer Therapeutics.

[18]  S. D'souza,et al.  E2F1 stability is regulated by a novel-PKC/p38β MAP kinase signaling pathway during keratinocyte differentiation , 2006, Oncogene.

[19]  A. Futerman,et al.  LASS5 Is a Bona Fide Dihydroceramide Synthase That Selectively Utilizes Palmitoyl-CoA as Acyl Donor* , 2005, Journal of Biological Chemistry.

[20]  C. Ong,et al.  Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. , 2005, Cancer research.

[21]  A. Kihara,et al.  Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. , 2005, The Biochemical journal.

[22]  K. Conklin.  Chemotherapy-Associated Oxidative Stress: Impact on Chemotherapeutic Effectiveness , 2004, Integrative cancer therapies.

[23]  Y. Hannun,et al.  Defects in Cell Growth Regulation by C18:0-Ceramide and Longevity Assurance Gene 1 in Human Head and Neck Squamous Cell Carcinomas* , 2004, Journal of Biological Chemistry.

[24]  A. Merrill,et al.  Two Mammalian Longevity Assurance Gene (LAG1) Family Members, trh1 and trh4, Regulate Dihydroceramide Synthesis Using Different Fatty Acyl-CoA Donors* , 2003, Journal of Biological Chemistry.

[25]  S. Y. Cajal,et al.  Role of the p38 MAPK pathway in cisplatin-based therapy , 2003, Oncogene.

[26]  H. Riezman,et al.  Upstream of Growth and Differentiation Factor 1 (uog1), a Mammalian Homolog of the Yeast Longevity Assurance Gene 1 (LAG1), RegulatesN-Stearoyl-sphinganine (C18-(Dihydro)ceramide) Synthesis in a Fumonisin B1-independent Manner in Mammalian Cells* , 2002, The Journal of Biological Chemistry.

[27]  Yusuf A. Hannun,et al.  The Ceramide-centric Universe of Lipid-mediated Cell Regulation: Stress Encounters of the Lipid Kind* , 2002, The Journal of Biological Chemistry.

[28]  N. Holbrook,et al.  Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.

[29]  K. Knudsen,et al.  RB-Dependent S-Phase Response to DNA Damage , 2000, Molecular and Cellular Biology.

[30]  S. Spiegel,et al.  Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate , 1996, Nature.

[31]  Richard A. Lerner,et al.  Immunogenic structure of the influenza virus hemagglutinin , 1982, Cell.

[32]  P. Galle,et al.  The longevity assurance homologue of yeast lag1 (Lass) gene family (review). , 2009, International journal of molecular medicine.

[33]  S. Saddoughi,et al.  Roles of bioactive sphingolipids in cancer biology and therapeutics. , 2008, Sub-cellular biochemistry.

[34]  Kyong-Tai Kim,et al.  Protein kinase Cdelta-mediated proteasomal degradation of MAP kinase phosphatase-1 contributes to glutamate-induced neuronal cell death. , 2006, Journal of cell science.